What is the Impact Factor of Pulmonary Pharmacology & Therapeutics?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Pulmonary Pharmacology & Therapeutics is 3.80, ranking in quartile Q2 of Web of Science (SCIE).

Is Pulmonary Pharmacology & Therapeutics indexed in Web of Science or Scopus?

Yes, Pulmonary Pharmacology & Therapeutics is indexed in Web of Science (SCIE, Q2 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.819 (Q2) and an H-index of 87.

Who publishes Pulmonary Pharmacology & Therapeutics and what is the Article Processing Charge (APC)?

Pulmonary Pharmacology & Therapeutics is published by Academic Press Inc.. The estimated Article Processing Charge (APC) is approximately $3,171 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Pulmonary Pharmacology & Therapeutics?

The official ISO-4 abbreviation of Pulmonary Pharmacology & Therapeutics is "PULM. PHARMACOL. THER" with common acronym "ypupt". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q2Scopus Q2SCImago #6,679Hybrid

Pulmonary Pharmacology & Therapeutics

Acronym:ypupt

•

Abbreviation (ISO):PULM. PHARMACOL. THER

•

Identifier (ISSN):1094-5539(Print)/1522-9629(Online)

•

Publisher:Academic Press Inc.

Official Website Submission Portal Compare

Clarivate IF (2026)

3.8↑ +1

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Pulmonary Pharmacology & Therapeutics

WoS Q2

Annual Impact Factor Metric

Current (2026):3.8

Scopus SJR & RankScopus Q2

0.819

#6,679

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

87 papers with at least that number of citations each

WoS: SCIE / JCRQ2

Self-Citation Rate0%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

62articles/year

20.79% Gold OA•89.19% Original Research

Aims & Scope

Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews. Research Areas Include: • All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary Toxicology.

Topics Covered (Recognized by AI)

Medicine91.9%Biology88.3%Internal medicine88%Immunology59.2%Chemistry55.4%Psychology51.5%Genetics50.5%Biochemistry49.8%Endocrinology45.9%Anesthesia44.9%Surgery44%Psychiatry42.5%Pathology42.1%Asthma38.9%Pharmacology37.3%Philosophy37.3%Physics37.1%Linguistics35.9%Lung33.9%Anatomy26.8%Geography24.5%Receptor24.1%Organic chemistry22.4%Meteorology21.8%

Primary Research Areas

Medicine Respiratory System

Official Website NLM PubMed Catalog Submission Portal SCImago Profile 1 Calls for Papers

1 calls

Special Issues

Calls for Papers

1 Calls for Papers · Automatically synced from ScienceDirect & publishers

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

PHARMACOLOGY & PHARMACY

Rank116/356

IndexSCIE

JCRSCIE2026

RESPIRATORY SYSTEM

Rank28/107

IndexSCIE

JCISCIE2026

PHARMACOLOGY & PHARMACY

Rank100/356

IndexSCIE

JCISCIE2026

RESPIRATORY SYSTEM

Rank31/107

IndexSCIE

Category	Index	Rank	Quartile
PHARMACOLOGY & PHARMACY	JCRSCIE	116/356	Q2
RESPIRATORY SYSTEM	JCRSCIE	28/107	Q2
PHARMACOLOGY & PHARMACY	JCISCIE	100/356	Q2
RESPIRATORY SYSTEM	JCISCIE	31/107	Q2

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF3.8

Articles / Year26

Total Citations11

2025

IF2.8

Articles / Year35

Total Citations82

2024

IF3.3

Articles / Year32

Total Citations208

2023

IF3.2

Articles / Year60

Total Citations511

2022

IF3.282

Articles / Year42

Total Citations413

Year	Impact Factor	Articles / Year	Total Citations
2026	3.8	26	11
2025	2.8	35	82
2024	3.3	32	208
2023	3.2	60	511
2022	3.282	42	413
2021	3.41	71	1,231
2020	2.681	74	1,224
2019	2.669	96	2,096
2018	2.406	82	1,685
2017	—	128	3,242
2016	—	69	1,550
2015	—	92	2,633

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #6,679Scopus Q2SCImago Profile

Scopus Coverage:1997-2026

•

Scopus Broad Areas:Medicine

Scopus Citation Rank (SJR)Q2

0.819

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2

Citations / Doc (2 years)

3.77

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,171 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations406

3-Year Documents123

Citable Documents117

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate46.6%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Biochemistry (medical)Q2

Medicine (miscellaneous)Q2

Pharmacology (medical)Q2

Pulmonary and Respiratory MedicineQ2

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

3区PHARMACOLOGY & PHARMACY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Pulmonary Pharmacology & Therapeutics (acronym: ypupt, abbr: PULM. PHARMACOL. THER, ISSN: 1094-5539) is a peer-reviewed international scholarly journal in the field of Medicine, published by Academic Press Inc. in England since 1997. The periodical holds a Journal Impact Factor (JIF) of 3.80, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 0.819 (Q2), an H-index of 87.

The journal enforces rigorous peer evaluation with an average review speed of 9.7周, a publication frequency of Bimonthly, an annual output of approximately 62 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,171 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.